

MEMO:

Submission of Clinical Trial Agreements (CTA) no longer required by BC Cancer REB

Please note that as of May 27, 2024, the BC Cancer REB no longer requires Clinical Trial Agreements to be attached to the REB application forms.

TCPS 2 Article 6.24 states that "[i]nstitutions shall make sponsor-researcher contracts available to REBs upon request". However, it has been BC Cancer REB's practice to routinely request these prior to initial approval, and with subsequent CTA revisions. All clinical trial contracts at BC Cancer are executed through the PHSA Technology Development Office (TDO), who are positioned to ensure that the requirements of TCPS 2 are met in sponsor-researcher contracts. REB review of CTAs is considered duplicative.

If the need arises for REB to review a CTA, this will be requested individually by contacting the Principal Investigator and study team directly.